These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34686147)

  • 21. Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis.
    Yang Z; Liang Y; Lin F; Zhang Z; Luo W; Zhang Y; Zhong R
    Int Immunopharmacol; 2018 Mar; 56():285-290. PubMed ID: 29414663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients.
    Zhao DT; Yan HP; Han Y; Zhang WM; Zhao Y; Liao HY
    Front Endocrinol (Lausanne); 2023; 14():1142177. PubMed ID: 38027142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease.
    Silveira MG; Mendes FD; Diehl NN; Enders FT; Lindor KD
    Liver Int; 2009 Aug; 29(7):1094-100. PubMed ID: 19291181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.
    Ahn JM; Paik YH; Min SY; Cho JY; Sohn W; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut Liver; 2016 Mar; 10(2):295-302. PubMed ID: 26347511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.
    Longo M; Crosignani A; Battezzati PM; Squarcia Giussani C; Invernizzi P; Zuin M; Podda M
    Gut; 2002 Aug; 51(2):265-9. PubMed ID: 12117892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
    Abdelaziz AO; Shousha HI; Said EM; Soliman ZA; Shehata AA; Nabil MM; Abdelmaksoud AH; Elbaz TM; Abdelsalam FM
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1384-1388. PubMed ID: 30179227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol.
    Wu KT; Kuo PL; Su SB; Chen YY; Yeh ML; Huang CI; Yang JF; Lin CI; Hsieh MH; Hsieh MY; Huang CF; Lin WY; Yu ML; Dai CY; Wang HY
    J Clin Lipidol; 2016; 10(2):420-5.e1. PubMed ID: 27055973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of fenofibrate for hepatic steatosis in rats after severe burn].
    Huang Z; Meng C; Chen J; Chen Y; Chen Y; Zhou T; Yang C
    Zhonghua Shao Shang Za Zhi; 2016 May; 32(5):277-82. PubMed ID: 27188486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
    Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
    Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
    J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
    Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
    Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of non-alcoholic fatty liver disease mediated by YAP.
    Chen P; Luo Q; Huang C; Gao Q; Li L; Chen J; Chen B; Liu W; Zeng W; Chen Z
    Hepatol Int; 2018 Jan; 12(1):26-36. PubMed ID: 29330836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of plasma lipoprotein components assessed by ultracentrifugation in primary biliary cirrhosis and chronic hepatitis.
    Tacikowski T; Milewski B; Dzieniszewski J; Nowicka G; Walewska-Zielecka B
    Med Sci Monit; 2000; 6(2):325-9. PubMed ID: 11208331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum lipid profile and hepatic steatosis of adult beta-thalassaemia patients with chronic HCV infection.
    Siagris D; Kouraklis-Symeonidis A; Christofidou M; Lekkou A; Papadimitriou C; Arvaniti V; Thomopoulos K; Tsamandas A; Zoumbos N; Labropoulou-Karatza C
    Eur J Gastroenterol Hepatol; 2005 Mar; 17(3):345-50. PubMed ID: 15716660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Jang H; Han N; Staatz CE; Kwak JH; Baek IH
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102227. PubMed ID: 37884091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis.
    Yilmaz B; Koklu S; Buyukbayram H; Yalçin K; Korkmaz U; Posul E; Can G; Kurt M
    Afr Health Sci; 2015 Sep; 15(3):714-8. PubMed ID: 26957957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical study of non-alcoholic fatty liver disease and its combined the chronic HBV infection].
    He J; Zeng YL; Li W; Guo EE; Li JL; Kang Y; Shang J
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):618-622. PubMed ID: 29056013
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of langerhans cell infiltrate by CD1a immunostain in liver biopsy for the diagnosis of primary biliary cirrhosis.
    Graham RP; Smyrk TC; Zhang L
    Am J Surg Pathol; 2012 May; 36(5):732-6. PubMed ID: 22498823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.